Prix Actavia Life Sciences Inc (RASP)

Actavia Life Sciences, Inc. is a biotechnology company, which engages in the development of therapeutics for the treatment of leukemia and lymphoma diseases. The company is headquartered in New York City, New York and currently employs 1 full-time employees. The company went IPO on 2014-03-28. The firm is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. The company develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.